Affiliate Disclosure | We may earn a referral fee if you start a program through links on this page. This does not influence our clinical conclusions — the medication recommendation on this page is evidence-led. | Editorial Standards
The Best GLP-1 for Insulin Resistance (2026), Backed by Head-to-Head Evidence
By WPG Research Team | Last verified: | Last updated:
Tirzepatide is the best GLP-1 for insulin resistance.
That’s the short answer. Here’s why it holds up: In SURPASS-2 — the key large head-to-head trial with published insulin-resistance marker analysis — tirzepatide cut HOMA2-IR by 15.5% to 24.0% at week 40. Semaglutide 1mg cut it by 5.1%. That’s roughly 3 to 5 times more improvement, and tirzepatide also pulled ahead on fasting insulin and C-peptide. A separate 28-week study using the gold-standard hyperinsulinemic-euglycemic clamp confirmed tirzepatide produced greater insulin-sensitivity gains than semaglutide — gains not fully explained by weight loss alone.
For most people, the medication answer ends there. The harder part is figuring out how to actually get it.
Quick access map:
- Have insurance? Check your plan’s GLP-1 coverage with Ro — free check, plus they handle the prior-auth paperwork.
- Paying cash for FDA-approved branded tirzepatide? Ro lists Zepbound KwikPen at $299 for 2.5mg, $399 for 5mg, and $449 for 7.5mg–15mg with the manufacturer offer.
- Paying cash for compounded tirzepatide? Eden starts as low as $129 the first month and lists compounded tirzepatide first month at $249, with a typical range of $129–$329.
- Can’t take injections? SHED sells GLP-1 Liquid Drops starting at $229.
- Want metabolic lab work alongside? Enhance.MD tiered programs run $49–$189 the first month with labs every six months.
One wrinkle worth knowing before you click anything:
Insulin resistance by itself isn’t an FDA-approved reason to prescribe any GLP-1. A diagnosis code for insulin resistance exists (E88.819), but that doesn’t make it a covered indication or a reliable insurance-coverage door. Your real access path depends on what’s behind your insulin resistance — PCOS, prediabetes, type 2 diabetes, BMI, your other conditions. The good news: most people who land on this page already qualify through one of those overlapping diagnoses.
What we actually verified for this page
Pricing checked across 8 telehealth programs (Ro, Eden, Sesame Care, SHED, Enhance.MD, MEDVi, Yucca Health, Trim Rx) on . Clinical evidence pulled from FDA prescribing labels, FDA regulatory pages, and primary trial publications in J Clin Endocrinol Metab, Diabetes Obes Metab, J Endocr Soc, and Lilly’s SURMOUNT-1 disclosures. We’re an independent comparison resource. We earn affiliate commissions on some links — this does not change our clinical conclusions.
What Is the Best GLP-1 for Insulin Resistance?
Quick answer
Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for obesity) has the strongest published head-to-head evidence on insulin-resistance markers, especially against semaglutide 1mg in SURPASS-2. Its dual GIP and GLP-1 receptor activity produces both substantial weight loss and insulin-sensitivity gains that single-receptor GLP-1 medications can’t fully match. Semaglutide remains a strong option when insurance coverage, oral access, cardiovascular outcome data, or MASH approval is the priority.
Every number below comes from primary clinical literature — citations follow the table.
Insulin resistance marker reduction: GLP-1 head-to-head
| Medication | Drug class | Best HOMA2-IR result | Population studied | Direct head-to-head? |
|---|---|---|---|---|
| Tirzepatide (Mounjaro/Zepbound) | Dual GIP + GLP-1 receptor agonist | HOMA2-IR ↓ 15.5%–24.0% at 40 weeks (5/10/15mg) | T2D adults on metformin (SURPASS-2) | Yes (vs. semaglutide 1mg) |
| Semaglutide (Ozempic/Wegovy) | GLP-1 receptor agonist | HOMA2-IR ↓ 5.1% at 40 weeks (1mg) | T2D adults on metformin (SURPASS-2 comparator) | Yes (comparator arm) |
| Liraglutide (Saxenda/Victoza) | GLP-1 receptor agonist, daily injection | Significant HOMA-IR reduction in PCOS and obesity trials | Various: T2D, PCOS, obesity | No direct head-to-head with tirzepatide on IR markers |
| Dulaglutide (Trulicity) | GLP-1 receptor agonist, weekly | Modest HOMA-IR reduction (AWARD trials) | T2D adults | No direct head-to-head with tirzepatide on IR markers |
| Orforglipron (Foundayo) | Oral GLP-1 receptor agonist (small molecule) | IR-specific data still maturing | Obesity / overweight + comorbidity | No direct head-to-head on IR markers yet |
Sources: Heise et al., J Clin Endocrinol Metab 2024 (SURPASS-2 IR analysis); Lee et al., J Endocr Soc 2023 (SURPASS-1 monotherapy); Mather et al., Diabetes Obes Metab 2025 (clamp study); Eli Lilly SURMOUNT-1 disclosures (Aug and Nov 2024); FDA prescribing information for Mounjaro, Zepbound, Wegovy, Ozempic, Saxenda, Trulicity, Foundayo.
What HOMA-IR Is, in Plain Terms
HOMA-IR is a number your doctor calculates from a fasting blood draw — fasting glucose times fasting insulin, divided by a constant. Lower is better.
Common reference ranges suggest a HOMA-IR above 2.0–2.5 may indicate insulin resistance, with higher numbers more concerning, but cutoffs vary by lab, population, and assay. The right move isn’t to memorize a single threshold — it’s to use the same lab and same fasting method consistently over time, and interpret your number with your clinician.
If your HOMA-IR comes down using the same fasting method, that’s evidence your insulin-resistance markers are improving. Your clinician still has to read it alongside A1C, fasting glucose, triglycerides, waist circumference, liver markers, and how you actually feel.
Tirzepatide vs. Semaglutide for Insulin Resistance: What the Head-to-Head Evidence Shows
Quick answer
SURPASS-2 directly compared tirzepatide (5, 10, and 15mg) to semaglutide 1mg in 1,879 adults with type 2 diabetes over 40 weeks. Tirzepatide cut HOMA2-IR by 15.5%–24.0% versus 5.1% for semaglutide, with similar gaps on fasting insulin and C-peptide. A separate 28-week study using a hyperinsulinemic-euglycemic clamp confirmed tirzepatide produced greater insulin-sensitivity gains than semaglutide — gains not fully explained by weight loss alone.
SURPASS-2 — the key head-to-head with insulin-resistance markers
Tirzepatide and semaglutide were tested side by side in adults with type 2 diabetes already on metformin. After 40 weeks:
- HOMA2-IR reduction: 15.5% (tirzepatide 5mg), 21.7% (10mg), 24.0% (15mg). Semaglutide 1mg: 5.1%. The gap was statistically significant (p < .05) at every tirzepatide dose.
- Fasting C-peptide: dropped 5.2%–6.0% with tirzepatide 10/15mg. Rose 3.3% with semaglutide.
- Fasting glucagon: dropped 53.0%–55.3% with tirzepatide 10/15mg vs. 47.7% with semaglutide.
- A1C and weight loss: tirzepatide beat semaglutide at every baseline insulin-resistance level.
Translation: tirzepatide didn’t only produce more weight loss. It produced more pancreatic beta-cell rest (lower C-peptide) and more glucagon suppression — both independent reasons your insulin-resistance markers can improve.
SURMOUNT-1 — the three-year prediabetes story
The SURMOUNT-1 trial followed 1,032 adults with prediabetes and obesity or overweight on tirzepatide for 176 weeks. Lilly’s three-year disclosure reported:
- 94% relative risk reduction in progression to type 2 diabetes versus placebo.
- 22.9% average weight loss on the 15mg dose.
- Roughly 99% of participants remained diabetes-free during the treatment period.
- Number needed to treat = 9 — treat 9 patients to prevent one new case of diabetes over the study window.
This is one of the strongest pieces of evidence anyone has for slowing the slide from prediabetes to type 2 diabetes in adults with obesity or overweight. For comparison, the landmark Diabetes Prevention Program reduced diabetes incidence by 58% with lifestyle intervention and 31% with metformin over a mean 2.8 years. Tirzepatide’s effect size is in a different category.
The clamp study — separating drug effect from weight loss
A common pushback: “Sure tirzepatide improves insulin-resistance markers, but that’s just because you lost more weight on it.” The Mather 2025 analysis tested that directly using a hyperinsulinemic-euglycemic clamp — the medical gold standard for measuring how well your tissues take up glucose.
Tirzepatide’s insulin-sensitivity improvement correlated tightly with weight loss (R = −0.656). Semaglutide’s correlation was much weaker (R = −0.268). Translation: pound for pound, tirzepatide’s metabolic benefit comes from both weight loss and drug-specific effects that semaglutide can’t match. The GIP receptor isn’t a passenger — it’s pulling its own weight.
Check FDA-approved tirzepatide coverage with your insurance
Run Ro’s Free Insurance Coverage CheckFree check. Ro contacts your plan and handles prior authorization paperwork.
Where Semaglutide Still Wins (the honest version)
Tirzepatide isn’t the right answer for everyone. Three honest cases where semaglutide is the better fit:
1. You have established cardiovascular disease and your priority is preventing a heart attack or stroke.
Wegovy showed a 20% reduction in major adverse cardiovascular events in the SELECT trial. Tirzepatide’s CV outcome trial is still pending. If you’ve already had a cardiac event, that data matters more than a HOMA2-IR percentage point.
2. You have moderate-to-advanced fatty liver fibrosis (MASH).
Wegovy injection is FDA-approved for MASH in adults with moderate-to-advanced liver fibrosis, based on liver-fibrosis improvement data. Tirzepatide hasn’t reached that approval yet. Ordinary fatty liver without that biopsy or imaging diagnosis is a different conversation.
3. You strongly prefer an oral pill, or your insurance specifically covers semaglutide.
Wegovy comes as both injection and pill. Tirzepatide is injection-only as of this writing. If your insurance specifically covers Wegovy or Ozempic and not Zepbound/Mounjaro, semaglutide is your practical path.
If any of those fit you, our Best GLP-1 for Diabetes guide covers the semaglutide path in detail. For everyone else — particularly anyone whose primary issue is insulin resistance, prediabetes, or PCOS — tirzepatide has the stronger case.
How Do GLP-1 Medications Improve Insulin Resistance?
Quick answer
GLP-1 medications improve insulin-resistance markers through three pathways: (1) substantial weight loss reduces visceral fat and ectopic lipid in liver and muscle, restoring cell-level insulin sensitivity; (2) lower fasting glucagon, slower gastric emptying, and beta-cell rest reduce the glucose load your pancreas has to chase; and (3) for tirzepatide specifically, direct GIP receptor activation appears to improve how fat tissue itself responds to insulin — an effect that persists even after accounting for weight loss.
Pathway 1: Insulin sensitivity through weight loss
When fat accumulates around your organs (visceral fat) and inside your liver and muscle cells (ectopic lipid), those tissues stop responding to insulin properly. That’s the cellular-level definition of insulin resistance. Lose enough weight — particularly visceral and ectopic — and the cells start listening to insulin again.
GLP-1s drive substantial weight loss. SURMOUNT-1 produced 22.9% average weight loss on tirzepatide 15mg over 176 weeks. STEP-1 produced about 14.9% on semaglutide 2.4mg over 68 weeks. That’s the kind of weight loss that produces clinically meaningful metabolic-marker improvements in the studied populations.
But weight loss isn’t the whole story. If it were, the head-to-head trials would show semaglutide and tirzepatide producing equal HOMA2-IR reductions per pound lost. They don’t.
Pathway 2: Beta-cell rest and glucagon suppression
When your pancreas has been pumping out extra insulin for years to compensate for resistant cells, the insulin-producing beta cells get tired. Markers of beta-cell stress (proinsulin/C-peptide ratios) climb.
In SURPASS-1, tirzepatide monotherapy reduced fasting proinsulin by 49%–55% and intact proinsulin/C-peptide ratios by 47%–49% over 40 weeks. Tirzepatide also reduced fasting glucagon — the hormone that tells your liver to dump glucose into the bloodstream — by more than semaglutide did head-to-head.
When your pancreas stops being beaten up and your liver stops being told to overshoot glucose, your insulin-resistance markers have actual room to improve.
Pathway 3: The GIP receptor’s role (the tirzepatide difference)
GLP-1 (the hormone) and GIP (glucose-dependent insulinotropic polypeptide, another gut hormone) both signal the pancreas to release insulin after meals. GIP also appears to influence how fat tissue handles insulin and glucose.
Semaglutide hits the GLP-1 receptor only. Tirzepatide hits both GIP and GLP-1.
The Mather 2025 clamp analysis — the most precise way to measure insulin sensitivity in living humans — suggests tirzepatide produces fat-tissue insulin-sensitivity gains that aren’t fully explained by weight loss. The dual mechanism appears to do something a single agonist can’t. This is why tirzepatide leads on this page — not because it’s newer or more profitable — because the mechanism and the head-to-head data line up.
Which GLP-1 Path Fits Your Situation?
Quick answer
The right GLP-1 for insulin resistance depends on what’s driving the insulin resistance. Type 2 diabetes opens the easiest insurance path. Obesity (BMI ≥30) or overweight with a related condition (BMI ≥27 + comorbidity) opens the FDA-approved weight-management path. PCOS by itself is not an FDA-approved indication. Isolated insulin resistance is also not an FDA-approved indication, so the practical route is usually a clinician-supervised cash-pay or off-label discussion.
| Your situation | Medication to ask about | FDA-approved path? | Best access route | Est. monthly cost |
|---|---|---|---|---|
| Type 2 diabetes + insulin resistance | Tirzepatide (Mounjaro) | Yes — Mounjaro for T2D | Insurance-first → Ro insurance concierge | $25–$200 with coverage; $299–$449 cash branded |
| Obesity (BMI ≥30) + insulin resistance | Tirzepatide (Zepbound) | Yes — Zepbound for obesity | Insurance check → Ro; cash branded → Ro; compounded → Eden | $25–$449 |
| Overweight (BMI 27–29.9) + weight-related condition | Tirzepatide (Zepbound) | Yes — Zepbound with comorbidity | Same as above; comorbidity must be documented | $25–$449 |
| Prediabetes + BMI eligibility | Tirzepatide (Zepbound) | Via obesity/overweight + condition pathway | Insurance → Ro; compounded → Eden | $25–$329 |
| PCOS + insulin resistance | Tirzepatide (via obesity criteria); semaglutide also studied in PCOS RCTs | PCOS not an FDA-approved indication — access via BMI criteria | BMI ≥27 + comorbidity → Zepbound path or cash-pay | $129–$449 |
| Metabolic syndrome | Tirzepatide (Zepbound) | Via obesity/overweight pathway if BMI qualifies | Insurance → Ro; compounded → Eden | $129–$449 |
| Insulin resistance + BMI <27, no diabetes, no PCOS | Semaglutide or tirzepatide off-label; metformin as first-line alternative | No FDA-approved indication — cash-pay or clinician-supervised off-label only | Cash-pay compounded → Eden; discuss metformin with your PCP first | $129–$329 |
Short decision block
- Want FDA-approved + insurance help? → Ro
- Want Costco / self-pay branded? → Sesame Care
- Want cash-pay compounded and accept the extra verification? → Eden (broad fit), SHED (oral drops), or Enhance.MD (with labs)
3 Access Pathways: Insurance, Branded Cash, Compounded
Pricing verified . Pricing changes frequently — verify at checkout before paying.
1Insurance + FDA-Approved (the cheapest path if it works)
If your plan covers Mounjaro for type 2 diabetes or Zepbound for obesity, your out-of-pocket can be as low as $25–$200/month after copay and deductible. The hard part is finding out whether it’s covered and getting prior authorization through.
Ro’s free GLP-1 Insurance Coverage Checker scans your specific plan and tells you what it covers. If the plan covers it but requires prior authorization, Ro’s insurance concierge submits the paperwork.
Run Ro’s Free Insurance Coverage Check2Cash-Pay FDA-Approved Branded
If insurance won’t cover it, the next-cheapest FDA-approved path is cash-pay branded.
Ro publishes Zepbound KwikPen pricing at the manufacturer offer:
- 2.5mg: $299/month
- 5mg: $399/month
- 7.5mg–15mg: $449/month
- Missed refill or check-in timing can move higher-dose pricing to $499 or $699
Plus Ro Body membership for clinical support: $39 first month, then $149/month ongoing, or as low as $74/month with annual prepay.
Sesame Care offers Costco-member self-pay on Wegovy and Ozempic at dose-specific prices: $199 for the first two fills of certain lower-dose injections (limited-time offer through June 30, 2026), $349 for some maintenance strengths, $499 for Ozempic 2mg; Wegovy pill $149 for lower doses and $299 for higher doses.
3Cash-Pay Compounded
Pricing typically runs $129–$329/month all-in.
- Eden — broadest fit for most cash-pay shoppers. Compounded plans from $129 first month, compounded tirzepatide first month at $249, typical range $129–$329. Eden also lists branded options but at much higher cash-pay prices ($1,399/month Zepbound, $1,695/month Wegovy) — Eden is the value play for compounded, not branded.
- SHED — specializes in oral GLP-1 options for needle-averse shoppers. GLP-1 Liquid Drops starting at $229.
- Enhance.MD — pairs compounded GLP-1 (or combination) with metabolic lab testing every six months. GLP-1 Core (semaglutide): $49 first month / $212/month after. GLP-1 Advanced (tirzepatide): $99 first month / $280/month after. GLP-1 Elite (sema + tirz): $189 first month / $322/month after.
- MEDVi — offers a deep compounded menu. Material caveat: the FDA issued a February 20, 2026 warning letter to MEDVi over claims about compounded semaglutide and tirzepatide products. We do not lead with MEDVi on this page. Read the FDA warning letter directly and verify current claims and pharmacy disclosures before paying.
What to verify before paying a compounded provider
- Disclosed pharmacy partner — a reputable telehealth provider names the pharmacy and identifies whether it’s a 503A or 503B facility.
- US-based, state-licensed pharmacy — verify on the state pharmacy board’s public registry.
- Real clinician access — not just paperwork; a licensed prescriber who reviews your case and is reachable.
- Clear cancellation and refund policies — compounded programs sometimes auto-renew aggressively. Read the fine print.
- Honest formulation disclosure — programs that describe compounded products as “the same as” or a “generic version of” FDA-approved drugs are making claims the FDA has flagged as false or misleading.
Which Online Provider Fits Insulin-Resistance GLP-1 Treatment?
Quick answer
For FDA-approved branded medication and insurance support, Ro is the strongest fit — they handle prior auth, list dose-specific Zepbound KwikPen pricing from $299 to $449 with the manufacturer offer, and have a dedicated GLP-1 insurance concierge. For cash-pay compounded with the broadest formulary, Eden runs $129–$329/month. For oral drops, SHED starts at $229. For premium clinical care with labs every six months, Enhance.MD’s tiered programs run $49–$189 first month and $212–$322 ongoing. For Costco-member self-pay on Wegovy and Ozempic, Sesame Care.
Ro — best for insurance + FDA-approved
Ro’s pitch is straightforward: they’re the only major telehealth GLP-1 program that runs insurance coverage checks for free, handles prior authorization, and offers a clear dose-by-dose cash-pay menu for FDA-approved Zepbound, Foundayo, Wegovy pen, Wegovy pill, and Ozempic. Ro Body membership: $39 first month, $149/month ongoing, or as low as $74/month with annual prepay. Medication is separate and dose-specific.
Best for: Anyone with insurance who wants to use it; anyone who wants FDA-approved branded medication; anyone who wants the option to switch between formulations without changing providers.
Honest tradeoff: Ro does not lead with compounded. If your only path is cash-pay compounded because of cost, Eden is the better starting point.
Check Insurance Coverage with RoEden — best for cash-pay broad fit (compounded)
Eden offers compounded tirzepatide and compounded semaglutide for cash-pay shoppers, plus FDA-approved Wegovy and Zepbound for shoppers who want both options visible in one place. Compounded plans start as low as $129 the first month, with compounded tirzepatide first month at $249 and a typical range of $129–$329.
Best for: Cash-pay shoppers without insurance coverage; anyone who wants a clean broad cash-pay program.
Honest tradeoff: Compounded medications are not FDA-approved. If you want FDA-approved branded at the lowest cash price, Ro is the better path. Eden’s branded prices are much higher — Zepbound around $1,399/month and Wegovy around $1,695/month.
See Eden PricingSHED — best for oral drops / no-injection
SHED specializes in oral GLP-1 options for shoppers who can’t or won’t do weekly injections. Their GLP-1 Liquid Drops start at $229, with provider review. Depending on health needs, a clinician may recommend a specific compounded GLP-1 option.
Best for: Needle-averse shoppers; anyone whose primary objection to GLP-1s has been the injection.
Honest tradeoff: Oral and sublingual GLP-1 formulations have less head-to-head efficacy data than injectable formulations. Tirzepatide (the medication with the strongest insulin-resistance marker evidence) is not available as compounded oral drops in most programs.
See SHED’s Oral DropsEnhance.MD — best for lab-guided / premium
Enhance.MD pairs compounded tirzepatide or semaglutide (or a combination protocol) with metabolic lab testing every six months. If you want to actually track HOMA-IR, fasting insulin, ALT, and triglycerides over time, this is the cleanest “I want data on my progress” option.
- GLP-1 Core (semaglutide): $49 first month / $212/month after
- GLP-1 Advanced (tirzepatide): $99 first month / $280/month after
- GLP-1 Elite (sema + tirzepatide): $189 first month / $322/month after
Best for: Plateau patients; PCOS patients tracking metabolic markers; anyone who wants quantitative progress beyond the scale.
See Enhance.MD PricingSesame Care — best for Costco-member FDA-approved cash-pay
Sesame Care lets Costco members self-pay for Wegovy or Ozempic at dose-specific prices: $199 for the first two fills of certain lower-dose injections (limited-time offer through June 30, 2026), $349 for some maintenance strengths, and $499 for Ozempic 2mg. Wegovy pill is $149 for lower doses and $299 for higher doses.
Honest tradeoff: Less hand-holding than Ro on insurance work. If you might have coverage and want help navigating it, Ro is more efficient. You also need a Costco membership.
See Sesame Care PricingFull provider comparison
| Provider | Best at | Starting price | Insurance? | Standout fit |
|---|---|---|---|---|
| Ro | Insurance + FDA-approved branded | $39 first month + $299–$449 medication | Yes — concierge handles PA | FDA-approved primary path |
| Eden | Cash-pay broad-fit compounded | $129–$329/mo all-in (compounded) | No (cash) | Broadest cash-pay default |
| SHED | Oral drops / no-injection | $229+ starting (Liquid Drops) | No (cash) | Needle-averse |
| Enhance.MD | Lab-guided premium | $49–$189 first month / $212–$322 ongoing | No (cash) | Plateau / metabolic protocol |
| Sesame Care | Costco self-pay branded | $199 first two fills (limited-time) / $349 maintenance | Mixed | Costco-member Wegovy/Ozempic |
| MEDVi | Deepest compounded menu (verify carefully) | Verify current at checkout | No (cash) | Use only after independent verification — FDA warning letter Feb 2026 |
Not sure which provider fits? Take the 60-second match quiz.
Take the 60-Second Match Quiz →Maps your diagnosis, insurance, injection preference, and budget to the strongest fit. No email required to see results.
Safety, Labs to Check, and Who Should Not Start a GLP-1
What labs should you check before asking for a GLP-1?
Useful baseline labs:
| Lab test | Why it matters |
|---|---|
| Fasting glucose + fasting insulin → HOMA-IR | Directly measures your baseline insulin resistance; the number to track over time |
| HbA1c | Flags prediabetes (5.7%–6.4%) or diabetes (≥6.5%); affects which FDA-approved indication applies to you |
| Fasting lipids (triglycerides, HDL, LDL) | Triglycerides >150 and HDL <40 (men)/<50 (women) are metabolic syndrome criteria; both improve on GLP-1s |
| ALT / AST (liver enzymes) | Elevated ALT may indicate fatty liver (MASLD/MASH); GLP-1s improve fatty liver, but baseline matters |
| Creatinine / eGFR | Kidney function; GLP-1 labels emphasize monitoring for acute kidney injury with severe GI side effects |
| TSH (thyroid) | Untreated hypothyroidism can mimic insulin resistance; TSH screens for this before starting |
| Blood pressure | Baseline for metabolic syndrome criteria and comorbidity documentation (BMI 27+ + hypertension = Zepbound eligibility) |
Key safety considerations
- Pancreatitis: Rare but documented. Severe, persistent abdominal pain that radiates to your back, especially with vomiting, needs immediate medical attention.
- Gallbladder disease: GLP-1s and rapid weight loss both increase gallstone risk. Discuss with your clinician if you have a history of gallbladder issues.
- Severe gastroparesis: GLP-1s slow gastric emptying. A problem if you already have severe stomach motility issues.
- Retinopathy: People with established diabetic retinopathy may experience temporary worsening when blood sugar drops rapidly. Discuss with your endocrinologist before starting.
- Kidney disease: GLP-1 labels emphasize monitoring for acute kidney injury when severe GI side effects cause dehydration.
- Hypoglycemia: GLP-1 monotherapy rarely causes low blood sugar — but if you’re using insulin or sulfonylureas (glipizide, glyburide, glimepiride), the combination can. Your clinician will likely lower those doses when you start.
Pregnancy and contraception
GLP-1s should be discontinued before conception (per the labels for Mounjaro, Zepbound, Wegovy, and Ozempic). Animal studies have shown adverse fetal outcomes; human data is limited. The Zepbound and Mounjaro labels specifically note that tirzepatide may reduce the effectiveness of oral contraceptives around starting and dose escalations.
If you’re a PCOS patient hoping the medication will help your fertility: yes, it often does (by improving insulin resistance and ovulation). But you’ll need backup contraception while you’re on it, then a planned washout before trying to conceive.
Who should not start a GLP-1 without close clinical guidance
- Anyone with personal or family history of medullary thyroid carcinoma or MEN-2 (absolute contraindication)
- People with prior pancreatitis
- People with severe, symptomatic gastrointestinal disease
- People with kidney disease (need clinician guidance, especially around hydration)
- People with active diabetic retinopathy
- People currently pregnant or actively trying
- People using insulin or sulfonylureas (need dose-adjustment supervision)
- People with current or past eating disorder
Condition-Specific: PCOS, Prediabetes, Metabolic Syndrome, and Type 2 Diabetes
PCOS and insulin resistance
Insulin resistance is central to PCOS — it’s not a side effect of the condition, it’s the engine behind much of what makes PCOS hard to manage: the weight gain, the cycle issues, the cravings, the cystic acne. So “which GLP-1 helps PCOS insulin resistance?” is really “which GLP-1 helps insulin resistance?” — and tirzepatide is still the answer.
A 2025 systematic review and meta-analysis in Scientific Reports found that GLP-1 receptor agonists significantly reduced body weight, BMI, fasting insulin, 2-hour post-glucose-tolerance-test glucose, and HOMA-IR in women with PCOS — particularly those with obesity or metabolic complications.
Two PCOS-specific things matter:
- PCOS is not an FDA-approved indication for any GLP-1. Insurance won’t cover a GLP-1 for “PCOS.” Your access door is the overlapping conditions (obesity, T2D, BMI 27+ with comorbidity).
- Pregnancy planning is non-negotiable. Tirzepatide may reduce the effectiveness of oral contraceptives around starting and dose changes. GLP-1s should be stopped before conception. Have this conversation with a clinician before starting.
For a PCOS-specific walkthrough including the fertility/cycle-restoration angle, see our Best GLP-1 for PCOS guide.
Prediabetes (HbA1c 5.7%–6.4%)
The SURMOUNT-1 3-year data is one of the strongest pieces of evidence anyone has for slowing the drift from prediabetes to type 2 diabetes. 94% relative risk reduction in T2D progression over 176 weeks of tirzepatide. For comparison, the landmark Diabetes Prevention Program reduced diabetes incidence by 58% with lifestyle intervention and 31% with metformin over a mean 2.8 years. Tirzepatide’s effect size is in a different category.
Practical access path:
- BMI ≥30 with prediabetes → Zepbound qualifies on the obesity indication if your plan covers obesity
- BMI 27–29.9 with prediabetes → Zepbound qualifies if you also have hypertension, dyslipidemia, sleep apnea, fatty liver, or another weight-related comorbidity
- BMI <27 with prediabetes → cash-pay only; metformin is a strong, cheap, well-tolerated alternative worth discussing with your clinician
For the prediabetes deep-dive, see our Best GLP-1 for Prediabetes guide.
Metabolic syndrome
You meet the criteria for metabolic syndrome if you have any 3 of these 5: large waist circumference (≥40 inches men / ≥35 inches women), high triglycerides (≥150 mg/dL), low HDL (<40 mg/dL men / <50 mg/dL women), elevated blood pressure (≥130/85 or on BP meds), and elevated fasting glucose (≥100 mg/dL or on glucose-lowering meds).
GLP-1s — tirzepatide especially — improve every component. If you have metabolic syndrome and BMI 27+ with at least one comorbidity, the FDA-approved Zepbound path is open to you.
Type 2 diabetes
If you already have type 2 diabetes, the GLP-1 conversation isn’t really “which one for insulin resistance” anymore — it’s a comprehensive diabetes-management discussion involving A1C, weight, kidney function, cardiovascular risk, current medications, and cost. Tirzepatide (Mounjaro) and semaglutide (Ozempic) are both first-line options with strong glycemic and weight benefits. Tirzepatide produces larger A1C and weight reductions; semaglutide has more cardiovascular outcome data.
See our Best GLP-1 for Diabetes guide for the full diabetes-specific breakdown.
How We Picked: Methodology and What We Actually Verified
Quick answer
We started from the primary clinical literature on insulin-resistance markers — HOMA2-IR, fasting insulin, and clamp-measured insulin sensitivity — and prioritized head-to-head trials over indirect comparisons. We then layered FDA-approved access pathways, regulatory updates, and verified provider pricing across 8 telehealth programs. The medication recommendation (tirzepatide for insulin resistance) is evidence-led; provider rankings reflect evidence and reader fit first, with commercial relationships disclosed.
Source hierarchy for medical claims
- FDA prescribing labels for Mounjaro, Zepbound, Wegovy, Ozempic, Foundayo, Saxenda, and other approved products
- FDA regulatory pages on compounding policy, shortage-list status, and warning letters
- Primary clinical trial publications in peer-reviewed journals (J Clin Endocrinol Metab, NEJM, Diabetes Obes Metab, J Endocr Soc, Sci Rep)
- Manufacturer press disclosures for trials with results not yet in journal publications (e.g., SURMOUNT-1 3-year results)
- Major medical institution patient pages for general background only
- Provider websites — used only for verifying commercial facts (pricing, formulary, terms), never for medical claims
What we verified for this page on
- Mounjaro and Zepbound prescribing information including the boxed warning and indications
- Wegovy and Ozempic prescribing information including the MASH approval and CV risk-reduction indication
- SURPASS-2 published HOMA2-IR percentages by tirzepatide dose
- SURMOUNT-1 3-year results (94% relative risk reduction, NNT=9) from Eli Lilly disclosures
- Mather 2025 hyperinsulinemic-euglycemic clamp insulin-sensitivity correlations
- Ro Body membership pricing and dose-specific Zepbound KwikPen pricing
- Eden’s compounded and FDA-approved pricing pages
- Sesame Care’s Costco-member pricing including the limited-time $199 first-two-fills offer through June 30, 2026
- Enhance.MD’s three-tier pricing structure (Core / Advanced / Elite) and labs cadence
- SHED’s GLP-1 Liquid Drops starting price
- The FDA warning letter to MEDVi dated February 20, 2026
- FDA shortage-list status for semaglutide and tirzepatide (resolved; not currently on shortage list)
Affiliate disclosure
Some links on this page are affiliate links. We earn a commission if you complete a consultation or purchase through them. This does not change the price you pay or our editorial conclusions. The medication recommendation (tirzepatide for insulin resistance) and the provider-routing logic on this page are based on clinical evidence and reader fit.
Frequently Asked Questions
Which GLP-1 is best for insulin resistance?
Tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity) has the strongest published head-to-head evidence on insulin-resistance markers. In SURPASS-2, tirzepatide reduced HOMA2-IR by 15.5%–24.0% across doses, compared to 5.1% for semaglutide 1mg. Its dual GIP/GLP-1 mechanism produces direct fat-tissue insulin-sensitivity effects that GLP-1-only drugs do not have.
Can you take a GLP-1 for insulin resistance without diabetes?
Yes, but insulin resistance alone is not an FDA-approved indication, so insurance generally will not cover it on that basis. Access is typically through overlapping conditions — obesity (BMI ≥30), overweight + comorbidity (BMI ≥27 with a weight-related condition), type 2 diabetes, MASH with moderate-to-advanced fibrosis, or established CV disease. Cash-pay branded and cash-pay compounded are also options.
Are compounded GLP-1s FDA-approved?
No. Compounded semaglutide and tirzepatide products are not FDA-approved. The FDA has not reviewed any specific compounded formulation for safety, effectiveness, or quality. Verify the pharmacy, formulation, prescription basis, and current regulatory status before paying.
Is Mounjaro better than Ozempic for insulin resistance?
By every measured marker of insulin resistance in SURPASS-2, tirzepatide (Mounjaro) outperformed semaglutide 1mg (Ozempic) at every dose tested. Greater HOMA2-IR reduction, greater fasting insulin reduction, greater C-peptide reduction.
How much does a GLP-1 cost without insurance?
Cash-pay FDA-approved: Ro lists Zepbound KwikPen at $299 (2.5mg), $399 (5mg), and $449 (7.5–15mg) with the manufacturer cash-pay offer, plus a Ro Body membership ($39 first month, $149/month ongoing or as low as $74/month with annual prepay). Cash-pay compounded ranges $129–$329/month.
Does tirzepatide reverse insulin resistance?
Tirzepatide substantially reduces measured insulin-resistance markers. HOMA2-IR fell 15.5%–24.0% in 40-week trials. In SURMOUNT-1, a 94% relative risk reduction in progression to type 2 diabetes was reported over 176 weeks in adults with prediabetes and obesity or overweight versus placebo. Whether improvement persists after stopping depends on lifestyle changes built during therapy.
Will my insurance cover Mounjaro for insulin resistance?
Almost certainly not for "insulin resistance" alone. Insurance covers Mounjaro for type 2 diabetes. They cover Zepbound for obesity (BMI ≥30 or BMI ≥27 with a weight-related comorbidity), if your specific plan covers obesity treatment at all. Many employer-sponsored plans exclude obesity coverage. Ro's free GLP-1 Insurance Coverage Checker will tell you what your specific plan covers.
What labs should I check before starting a GLP-1?
Useful baseline labs include: fasting glucose and fasting insulin (to calculate HOMA-IR), HbA1c, fasting lipids (triglycerides, HDL, LDL), ALT/AST (liver enzymes), kidney function (creatinine, eGFR), TSH (thyroid), and blood pressure. These give you a baseline to track improvement and flag contraindications your clinician needs to know about.
Does Ozempic help insulin resistance?
Yes — semaglutide (Ozempic) reduces insulin-resistance markers, primarily through weight loss and beta-cell function improvement. The improvement is real and clinically meaningful. In head-to-head trials, it’s smaller than tirzepatide’s.
What’s the best GLP-1 for PCOS and insulin resistance?
Tirzepatide is the best-evidence option, though semaglutide and liraglutide also have published PCOS-specific RCTs. PCOS isn’t an FDA-approved indication for any GLP-1, so access is typically through obesity criteria (BMI ≥27 with comorbidity) or cash-pay programs. Pregnancy planning is critical — discuss contraception and washout timing with your clinician before starting.
How long does a GLP-1 take to improve insulin-resistance markers?
The strongest published HOMA2-IR improvements in the SURPASS analyses are reported at week 40. Many people notice appetite changes within the first 1–2 weeks of dose escalation. Plan to track your own response with baseline labs and follow-ups every 12 weeks during the first year.
What’s better for insulin resistance — tirzepatide or metformin?
They’re complementary, not direct competitors. Metformin is first-line for prediabetes and PCOS — it’s cheap, well-tolerated, and has decades of safety data. Tirzepatide produces dramatically larger effects on weight, insulin-resistance markers, and progression to diabetes, but at much higher cost. Many patients use both. The choice depends on your clinical picture, budget, and what you’ve already tried.
Are compounded GLP-1s legal in 2026?
Compounded GLP-1 products are not FDA-approved. After the FDA declared semaglutide and tirzepatide shortages resolved, the shortage-driven enforcement-discretion period ended in 2025. Any compounded route now needs a valid patient-specific prescribing basis, a licensed pharmacy, and current verification of pharmacy source and regulatory status. Reputable telehealth programs continue to operate, but the regulatory ground is firmer than during the shortage period.
What happens if I stop a GLP-1?
Most people regain a meaningful portion of weight within 12–24 months of stopping, and metabolic markers tend to drift toward baseline. GLP-1s are management, not cure. Some patients can step off with sustained lifestyle change, but plan for indefinite therapy unless your clinician has a specific reason to taper.
Do GLP-1 medications work for insulin resistance if I’m not overweight?
The clinical evidence is strongest in patients with overweight and obesity. Lean patients with insulin resistance (sometimes called TOFI — thin outside, fat inside, often with high visceral fat despite normal BMI) are an under-studied population. A clinician would need to evaluate your full picture before considering GLP-1s off-label cash-pay. Lifestyle intervention and metformin are usually first-line for this group.
Your Next Step
Quick answer
The right next step depends on your situation. If you’re insurance-curious, run the free coverage check. If you’re cash-pay and want compounded tirzepatide, start with a broad-fit cash-pay provider. If you’re not sure where you fall, take the 60-second match quiz — it routes you to the path with the strongest fit for your specific diagnosis, BMI, insurance, and budget.
You came here because you wanted a real answer to “best GLP-1 for insulin resistance.” The medication answer is tirzepatide. The access answer depends on you.
| Your situation | Start here |
|---|---|
| Have insurance and want to use it | Run Ro’s Free Coverage Check |
| Paying cash, want FDA-approved branded | See Ro’s Cash-Pay Tirzepatide Pricing |
| Costco member, want branded self-pay | See Sesame’s Costco Pricing |
| Paying cash, want compounded broad-fit | See Eden Pricing |
| Can’t take injections | See SHED’s Oral Drops |
| Want lab work included | See Enhance.MD Pricing |
| Not sure which fits | Take the 60-Second Match Quiz → |
Still not sure which GLP-1 program is right for you? Our free 60-second quiz maps your diagnosis, insurance, injection preference, safety flags, and budget to the medication and provider with the strongest evidence and best fit.
Start the 60-Second Match Quiz →No email required to see results.
Related guides
This guide is educational and does not replace medical advice. GLP-1 medications require evaluation by a licensed clinician. The right option depends on your full health history, current labs, medication list, pregnancy plans, insurance, and contraindications. Talk to your doctor before starting or changing any medication.
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We earn affiliate commissions on some links — our editorial conclusions are evidence-led and not influenced by commercial relationships.
Last verified: . We re-verify pricing and provider terms monthly, regulatory status monthly until stable, and clinical evidence quarterly.
Primary sources: Heise et al., J Clin Endocrinol Metab 2024 (SURPASS-2 IR analysis); Lee et al., J Endocr Soc 2023 (SURPASS-1 monotherapy); Mather et al., Diabetes Obes Metab 2025 (clamp study); Eli Lilly SURMOUNT-1 disclosures (Aug and Nov 2024); FDA prescribing information for Mounjaro, Zepbound, Wegovy, Ozempic, Saxenda, Trulicity, Foundayo; FDA.gov warning-letter database; ro.co/weight-loss/pricing; joinfound.com; tryeden.com; tryshed.com; enhance.md; sesamecare.com. All verified .